trending Market Intelligence /marketintelligence/en/news-insights/trending/xv3gpbw48hx8keyshbxdvq2 content esgSubNav
In This List

Genmab's cancer drug fails in late-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Genmab's cancer drug fails in late-stage study

Danish drugmaker Genmab A/S said the phase 3 trial of its medicine Arzerra failed to meet its main goal in treating a type of blood cancer.

The company was studying whether adding Arzerra to bendamustine was better for patients with indolent B-cell non-Hodgkin lymphoma who had stopped responding to Roche Holding AG's Rituxan, which is also known as rituximab.

Indolent B-cell non-Hodgkin lymphoma is a cancer of the white blood cells that grows and spreads slowly.

Bendamustine is marketed as Treanda by Teva Pharmaceutical Industries Ltd. in the U.S.

The study, known as Complement A+B, showed that the combination failed to perform better in stopping cancer from growing when compared to bendamustine alone.

Arzerra, or ofatumumab, along with Rituxan and Roche's Gazyva, belong to a class of drugs that target the CD20 molecule found on the surface of white blood cells.

The drug is approved in the U.S. and Europe for treating chronic lymphocytic leukemia, a cancer of the blood and bone marrow.

Swiss drugmaker Novartis AG said in January that it would withdraw Arzerra from the commercial market outside of the U.S. due to lower demand for the drug in those regions.